Alzheimer’s Disease is a common chronic condition, with predicted increasing prevalence. Nearly all people with Alzheimer will experience NeuroPsychiatric Symptoms (NPS). These NPS result in behavioral disturbances and cause a significant burden for both patients and their caregivers. Current treatment has only modest efficacy and severe side effects.
Namisol® in Alzheimer’s Disease
Δ9-THC has the potential for beneficial influences on NPS. The primary objective of the study is to evaluate the efficacy and safety of Namisol® on NPS in dementia.
Are you a patient and interested in participating in our trial, please follow the link below: